Get started
Live feed
·
PRReleasevia Quantisnow
Rapport Therapeutics Inc. logo

Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania

ByQuantisnow·Wall Street's wire, on your screen.
RAPPRapport Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RAPP (Rapport Therapeutics Inc.) and more on Quantisnow.